Table 2

Characteristics of analysed studies

Author
Patients
Saiura
180
ENG
129
FFCD
173
ArmADJ UFT/LVSurgery aloneADJ 5-FU/FASurgery aloneADJ 5-FU/FASurgery alone
Randomised
(analysed)
90
(88)
90
(89)
62
(52)
67
(55)
87
(86)
86
(85)
Male57 (64.8%)63 (70.8%)34 (65.4%)36 (65.4%)46 (53.5%)53 (62.4%)
Female31 (35.2%)26 (29.2%)28 (34.6%)31 (34.6%)40 (46.5%)32 (37.6%)
Median age62.3*
(8.5 SD)
64.4*
(9.2 SD)
63.5
(35-76)
60
(20-82)
63
(35-77)
63
(36-76)
Primary tumour
 Rectum36 (40.9%)31 (34.8%)14 (26.9%)17 (30.9%)35 (40.7%)34 (40.0%)
 Colon52 (59.1%)58 (65.2%)32 (61.5%)35 (60.0%)50 (58.1%)51 (60.0%)
 Unknown6 (11.5%)5 (9.1%)1 (1.2%)
Nodal status
 Negative41 (48.2%)29 (33.0%)24 (46.1%)26 (47.3%)46 (53.5%)39 (45.8%)
 Positive44 (51.8%)59 (67.0%)26 (50.0%)25 (45.4)39 (44.3%)43 (50.6%)
 Unknown2 (3.9.%)4 (7.3%)1 (1.2%)3 (3.5%)
Disease-free interval, years†
<1NANA18 (34.6%)21 (38.2%)42 (48.8%)39 (45.9%)
 >1NANA34 (65.3%)34 (61.8%)44 (51.2%)46 (54.1%)
Metastases
 Single37 (42.0%)44 (49.4%)33 (63.5%)37 (67.3%)59 (68.6%)59 (69.4%)
 Multiple51 (58.0%)45 (50.6%)19 (36.5%)18 (32.7%)27 (31.4%)26 (30.1%)
 Synchronous39 (43.3%)40 (44.9%)NANANANA
 Metachronous49 (55.7%)49 (55.1%)NANANANA
Maximum size, cm
 >521 (23.3%)18 (20.0%)NANA22 (25.6%)26 (30.6%)
<557 (76.7%)71 (80.0%)NANA64 (74.4%)59 (69.4%)
Metastatic site
 Liver88 (100%)89 (100%)44 (84.6%)46 (83.6%)86 (100%)85 (100%)
 Lung7 (13.5%)6 (10.9%)
 Unknown1 (1.9%)3 (5.4%)
  • *mean, †DFS in ENG study was calculate as <vs > 6 months (and not 12 months as in FFCD study.

  • ADJ, adjuvant; DFS, disease-free survival; ENG, European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada, Gruppo Italiano di Valutazione Interventi in Oncologia; FFCD, Federation Francophone de Cancerologie Digestive; 5-FU, fluorouracil; LV, leucovorin; UFT, uracil tegafur.